Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | Director · PRESIDENT, CHAIRMAN, CEO · 10% owner | August 16, 2025 | August 18, 2026 |
| FF EAI Robotics Ecosystem Inc.RTTR · Entity 7776 | Director | January 23, 2018 | January 26, 2018 |
| SOPHIRIS BIO INC.SPHS · Entity 152909 | Director | June 27, 2019 | June 28, 2019 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | January 09, 2026 | January 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dermata Therapeutics, Inc.
Report date August 16, 2025 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | 292,631 |
Reported balance
After 2026-08-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-16 · Grant · Acquired 170,068 · Balance 292,631 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469. F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series E Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 | IndirectBy Proehl Investment Ventures LLC | 1,360,544 |
Reported balance
After 2026-08-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-16 · Grant · Acquired 1,360,544 · Balance 1,360,544 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469. F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series F Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 | IndirectBy Proehl Investment Ventures LLC | 1,360,544 |
Reported balance
After 2026-08-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-16 · Grant · Acquired 1,360,544 · Balance 1,360,544 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469. F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series E Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 | IndirectBy Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | 170,068 |
Reported balance
After 2026-08-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-16 · Grant · Acquired 170,068 · Balance 170,068 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469. F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Series F Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 | IndirectBy Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | 170,068 |
Reported balance
After 2026-08-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-16 · Grant · Acquired 170,068 · Balance 170,068 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469. F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Pre-Funded Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Proehl Investment Ventures LLC | 1,360,544 |
Reported balance
After 2026-08-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-16 · Grant · Acquired 1,360,544 · Balance 1,360,544 F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock. F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469. F6: The pre-funded warrant has no expiration date. F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions. F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 24 |
Reported balance
Holding disclosure · report date 2025-08-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 24 |
| Common StockSEC Table I · non-derivative | IndirectBy Allison Taylor Proehl 2020 Irrevocable Trust | 7 |
Reported balance
Holding disclosure · report date 2025-08-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7 F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Meghan Proehl Wilder 2020 Irrevocable Trust | 3 |
Reported balance
Holding disclosure · report date 2025-08-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3 F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Proehl Investment Ventures LLC | 79,950 |
Reported balance
Holding disclosure · report date 2025-08-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 79,950 F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock.
F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469.
F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F6: The pre-funded warrant has no expiration date.
FF EAI Robotics Ecosystem Inc.
Report date January 23, 2018 · Filed January 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2028-01-23 | Direct | 30,000 |
Reported balance
After 2018-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-23 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests in twelve (12) equal monthly installments beginning on February 23, 2018 with the balance vesting on the 23rd day of each calendar month thereafter until vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve (12) equal monthly installments beginning on February 23, 2018 with the balance vesting on the 23rd day of each calendar month thereafter until vested in full.
SOPHIRIS BIO INC.
Report date June 27, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2029-06-26 | Direct | 20,000 |
Reported balance
After 2019-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-27 · Grant · Acquired 20,000 · Balance 20,000 F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program.
F2: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period.
TENAX THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09 | Direct | 30,000 |
Reported balance
After 2026-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-09 · Grant · Acquired 3,000 · Balance 30,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9,968.00 · Expires 2028-05-01 | Direct | 1 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,056.00 · Expires 2030-05-01 | Direct | 1 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3,200.00 · Expires 2031-06-10 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 100,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2035-07-01 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 80,000 |
| Common StockSEC Table I · non-derivative | Direct | 1,667 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,667 |
| Pre-Funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 | Direct | 31,654 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 31,654 F1: The pre-funded warrant has no expiration date. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 | Direct | 16,660 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 16,660 F2: The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The pre-funded warrant has no expiration date.
F2: The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2021 Filed Aug 17, 2021 16:38 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 17,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001094 · dermata_fm4aug172021.xml · nonDerivative · entry 2 PROEHL GERALD T · CIK 0001279191 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Allison Taylor Proehl 2020 Irrevocable Trust Disclosed balance after: 17,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. F8 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:38 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | PurchaseCommon Stock | 10,000 | $4.96 | $49,631.00 |
DisclosureSEC source: 0000905718-21-001094 · dermata_fm4aug172021.xml · nonDerivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director · President, CEO and Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Proehl Family Trust Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $5.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F8 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 10, 2021 Filed Jun 15, 2021 20:34 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001654954-21-006928 · section16.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-06-10 Read SEC document |
| May 01, 2020 Filed May 15, 2020 21:01 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001654954-20-005667 · section16.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2030-05-01 Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:31 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-19-039486 · doc4.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-26 F1 · security: Granted pursuant to the Company 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 20:59 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001209191-18-039919 · doc4.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-26 F1 · security: Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| May 01, 2018 Filed Apr 18, 2019 20:31 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001654954-19-004580 · section16.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common stock · 500 shares Expires 2018-05-01 Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 02:31 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001382963-18-000023 · edgar.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests in twelve (12) equal monthly installments beginning on February 23, 2018 with the balance vesting on the 23rd day of each calendar month thereafter until vested in full. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 20:35 UTC | SOPHIRIS BIO INC. SPHS · Entity 152909 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001209191-17-036799 · doc4.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-29 F1 · security: Granted pursuant to the Company's 2017 Non-Employee Director Compensation Program. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest and become exercisable monthly over a one year period. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 23:46 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | GrantStock Option (2015 Equity Incentive Plan) · Derivative | 7,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001382963-16-000267 · edgar.xml · derivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2026-11-29 F1 · derivative.exercise_date: Of the 7,000 shares granted, 730 shares were vested as of the grant date and the remaining 6,270 shares will vest ratably over the next 43 months. Read SEC document |
| November 23, 2016 Filed Nov 29, 2016 20:55 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 14,449 | $1.76 | $25,430.24 |
DisclosureSEC source: 0001354488-16-008600 · issuerdirect_section16.xml · nonDerivative · entry 2 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,882 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.73 to $1.79. Read SEC document |
| November 22, 2016 Filed Nov 29, 2016 20:55 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | PurchaseCommon Stock | 15,433 | $1.59 | $24,538.47 |
DisclosureSEC source: 0001354488-16-008600 · issuerdirect_section16.xml · nonDerivative · entry 1 PROEHL GERALD T · CIK 0001279191 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,433 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.65. The reporting person undertakes to provide to Tenax Therapeutics, Inc. (the "Company"), any security holder of the Company, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.